Dan Thomas - ALLIANCE PHARMA Other - Business Development Director

DVL Stock  EUR 0.43  0.01  2.38%   

Director

Dan Thomas is Business Development Director in Alliance Pharma Plc. Since joining Alliance in 2006 Dan has led Alliances MA and licensing activity completing over 17 deals. Dan has worked in senior management in the clinical research sector at Chiltern International and in the biotech research and diagnostics sector at RD Systems Europe responsible for international regional sales operations. Dan has worked in Canada Germany and France. He holds a first class honours degree in Applied Biochemistry from Brunel University. In 2011 Dan won the PLGAstraZeneca BD Executive of the Year award. since 2014.
Tenure 10 years

Similar Executives

Showing other executives

DIRECTOR Age

Randy LivingstonEHEALTH
60
Randall LivingstonEHEALTH
64
Roger MooreConsolidated Communications Hol
76
Richard LumpkinConsolidated Communications Hol
83
Andrea BrimmerEHEALTH
52
Jack OliverEHEALTH
49
Thomas GerkeConsolidated Communications Hol
61
Jennifer SpaudeConsolidated Communications Hol
N/A
Wayne WilsonConsolidated Communications Hol
69
Ellen TauscherEHEALTH
66
Timothy TaronConsolidated Communications Hol
67
Maribeth RaheConsolidated Communications Hol
69
Scott FlandersEHEALTH
61
Dale ParkerConsolidated Communications Hol
66
Michael GoldbergEHEALTH
60
ALLIANCE PHARMA (DVL) is traded on Berlin Exchange in Germany and employs 13 people.

ALLIANCE PHARMA Leadership Team

Elected by the shareholders, the ALLIANCE PHARMA's board of directors comprises two types of representatives: ALLIANCE PHARMA inside directors who are chosen from within the company, and outside directors, selected externally and held independent of ALLIANCE. The board's role is to monitor ALLIANCE PHARMA's management team and ensure that shareholders' interests are well served. ALLIANCE PHARMA's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, ALLIANCE PHARMA's outside directors are responsible for providing unbiased perspectives on the board's policies.
Sarah Robinson, Company Secretary
David Cook, Independent Non-Executive Director
Janice Timberlake, Director of Human Resources
Andrew Franklin, Finance Director, Director
John Dawson, CEO, Executive Director
Stephen Kidner, Other - Operations Director
Dan Thomas, Other - Business Development Director
Anthony Booley, Executive Director
Andrew Smith, Non-Executive Director
Nigel Clifford, Independent Non-Executive Director
Margaret Boulton, Other - Medical and Regulatory Affairs Director
Thomas Casdagli, Non-Executive Director
Peter Butterfield, Executive Director

ALLIANCE Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is ALLIANCE PHARMA a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards ALLIANCE PHARMA in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, ALLIANCE PHARMA's short interest history, or implied volatility extrapolated from ALLIANCE PHARMA options trading.

Pair Trading with ALLIANCE PHARMA

One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if ALLIANCE PHARMA position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ALLIANCE PHARMA will appreciate offsetting losses from the drop in the long position's value.
The ability to find closely correlated positions to ALLIANCE PHARMA could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace ALLIANCE PHARMA when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back ALLIANCE PHARMA - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling ALLIANCE PHARMA to buy it.
The correlation of ALLIANCE PHARMA is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as ALLIANCE PHARMA moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if ALLIANCE PHARMA moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for ALLIANCE PHARMA can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.
Pair CorrelationCorrelation Matching
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in ALLIANCE PHARMA. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors.
You can also try the Price Exposure Probability module to analyze equity upside and downside potential for a given time horizon across multiple markets.

Complementary Tools for ALLIANCE Stock analysis

When running ALLIANCE PHARMA's price analysis, check to measure ALLIANCE PHARMA's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ALLIANCE PHARMA is operating at the current time. Most of ALLIANCE PHARMA's value examination focuses on studying past and present price action to predict the probability of ALLIANCE PHARMA's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ALLIANCE PHARMA's price. Additionally, you may evaluate how the addition of ALLIANCE PHARMA to your portfolios can decrease your overall portfolio volatility.
Equity Valuation
Check real value of public entities based on technical and fundamental data
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Price Exposure Probability
Analyze equity upside and downside potential for a given time horizon across multiple markets
Insider Screener
Find insiders across different sectors to evaluate their impact on performance
Portfolio Backtesting
Avoid under-diversification and over-optimization by backtesting your portfolios
Equity Forecasting
Use basic forecasting models to generate price predictions and determine price momentum
Please note, there is a significant difference between ALLIANCE PHARMA's value and its price as these two are different measures arrived at by different means. Investors typically determine if ALLIANCE PHARMA is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, ALLIANCE PHARMA's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.